By Kassie McClung | The Frontier Apr 28, 2021
3 hrs ago
Shown is Tara Markley leaning against a brick wall. Markley is one of many Oklahomans continuing to face long-term health issues long after first contracting COVID-19. Ben Felder/The Frontier
Tara Markley ran full marathons before she was infected with COVID-19 in late December.
But since she got sick more than four months ago, sheâs barely been able to go on walks. Markley, 42, wants to play with her two young children, but once she gets moving she struggles to catch her breath. Her heart immediately starts to race.
Sheâs experienced brain fog, fatigue, headaches and joint aches. She has short-term memory loss, and her depression and anxiety have worsened.
Headlines: Severe Weather, KKK Flyers in Southern Oklahoma & Thunder Snaps Losing Streak
kosu.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kosu.org Daily Mail and Mail on Sunday newspapers.
La Jolla News Nuggets: Munk house, $14 million for UCSD, Community Center fundraising, more
lajollalight.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lajollalight.com Daily Mail and Mail on Sunday newspapers.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage to the nervous system, new research demonstrates.
“We are encouraged by these new analyses showing that early treatment with Ocrevus may significantly control disease progression in both relapsing-remitting MS and in primary progressive MS,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech (a member of the Roche Group), which makes Ocrevus, said in a press release.